{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-032121","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.242679+00:00","generated_at":"2026-06-05T00:49:19.272348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024","bullets":["Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.","Cash and equivalents $467.3M at year-end; expected to fund operations through 2026.","Topline GSBR-1290 Phase 2a obesity data (12-week) expected latter half of Q2 2024.","Phase 2b obesity study of GSBR-1290 planned to start Q4 2024.","R&D expenses $20.0M in Q4 2023 ($70.1M full year), up from $8.4M in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-032121","json":"https://secwatch.observer/filing/0001104659-24-032121.json","markdown":"https://secwatch.observer/filing/0001104659-24-032121.md","text":"https://secwatch.observer/filing/0001104659-24-032121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/tm248154d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:49:19.272348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"748304e4d17f440ef81a9ddf1c70cbea3746efb8","claim":"Structure Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net loss for the fourth quarter of 2023 totaled $24.5.","evidence_excerpt":"Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 totaled $24.5"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8296476bd1886f7a06a23ec5ec41bfbfd5994994","claim":"Structure Therapeutics Inc. reported the year ended December 31, 2023 results: net income For the year ended December 31, 2023, net loss totaled $89.6 million.","evidence_excerpt":"For the year ended December 31, 2023, net loss totaled $89.6 million, with non-cash stock-based compensation expense of $8.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"For the year ended December 31, 2023, net loss totaled $89.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}